Paradigm Shifts in Lipid Lowering

Expert cardiologists provide a brief overview of the standard of care for lipid disorders and focus on a rapidly emerging, newer treatment option for managing dyslipidemia.

EP. 1: Pathophysiology of Hypercholesterolemia and Cardiovascular Disease

March 22nd 2021

Manesh Patel, MD, discusses the pathophysiology of the relationship between hypercholesterolemia and cardiovascular disease.

EP. 2: Risk Factors for Developing Hyperlipidemia

March 22nd 2021

Expert panel of cardiologists provide their perspective on the specific population that may be at a risk of developing hyperlipidemia.

EP. 3: Identifying Patients at High Risk for CV Morbidity and Mortality

March 29th 2021

Norman Lepor, MD, FACC, FAHA, FSCAI, shares how he would identify and monitor patient populations at high risk for CV morbidity and mortality.

EP. 4: High Cholesterol Versus Familial Hypercholesterolemia

March 29th 2021

Linda Hemphill, MD, shares her views on how familial hypercholesterolemia impacts the assessment of high-risk patients.

EP. 5: Aggressive LDL Lowering in High-Risk Patients

April 5th 2021

Dean Karalis, MD, provides his perspective on intensive LDL lowering in patients with risk for high cholesterol and related disorders.

EP. 6: Mechanism of Action of Inclisiran in Lipid Lowering

April 5th 2021

Manesh Patel, MD, briefly addresses the mechanism of action of inclisiran as an adjunct therapy for lipid lowering in patients with high cholesterol.

EP. 7: Outcomes and Practical Implications of Newer Agents

April 12th 2021

Cardiologists briefly review the outcomes data and practical implications of novel treatment options for hyperlipidemia.

EP. 8: EPA in the Prevention of CV Risk

April 12th 2021

Panel of experts discuss the use and safety profile of purified icosapent ethyl compound (EPA) in prevention of CV risk.

EP. 9: Emerging Use of Inclisiran as Adjunct Therapy in Hyperlipidemia

April 19th 2021

Experts review in detail the emerging use of inclisiran as an adjunct therapy for lipid lowering in patients with high cholesterol.

EP. 10: Phase 3 ORION Trials for Inclisiran 

April 19th 2021

Norman Lepor, MD, FACC, FAHA, FSCAI, reviews the efficacy of inclisiran in terms of LDL reduction based on the pooled analysis of the phase 3 ORION trials.